Összesen 1 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM104619
035-os BibID:(cikkazonosító)3475 (WoS)000883850300001 (Scopus)85141641121
Első szerző:Madarász Kristóf (biológus)
Cím:Deep Molecular and In Silico Protein Analysis of p53 Alteration in Myelodysplastic Neoplasia and Acute Myeloid Leukemia / Madarász Kristóf, Mótyán János András, Bedekovics Judit, Miltényi Zsófia, Ujfalusi Anikó, Méhes Gábor, Mokánszki Attila
Dátum:2022
ISSN:2073-4409
Megjegyzések:Background: Mutation of the TP53 gene is one of the major drivers of myelodysplastic neoplasias (MDS) and acute myeloid leukemia with myelodysplasia-related changes (AML-MR). TP53 mutations present in these hematopoietic malignancies form a distinct molecular genetic cluster with a worse prognosis than without the alteration. However, besides well-characterized hot-spot variants, a significant proportion of TP53 alterations are of uncertain clinical significance. Methods: To enlighten so far unknown aspects, bone-marrow samples from altogether 77 patients are analyzed retrospectively with the diagnosis of AML-MR (26 cases), MDS-IB (12 cases), and MDS-LB (39 cases) according to WHO 2022 guidelines. Next-generation sequencing results are correlated with histological, cytogenetic, and survival data. Results: Twenty out of the 30 TP53 mutation types detected by NGS are not categorized in current public databases; thus, their clinical significance remained mysterious. Because of the interpretation difficulties and the absence of clinical correlations, pathogenicity is established based on in silico approaches. The 12 pathogenicity classification systems, as well as protein stability, protein?DNA, protein?protein interaction, and post-translational modification analyses are applied. We found statistically significant differences between AML/MDS groups considering p53 pathogenicity, protein structural changes, and overall survival. The largest number of abnormalities with the most severe consequences are found in AML-MR cases. Conclusions: These molecular and in silico protein data further support that MDS with increased-blast (MDS-IB) is an intermediate group between AML-MR and MDS with low-blast (MDS-LB) patients, which frequently progresses to AML and is therefore considered a pre-leukemic condition.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
in silico bioinformatic analysis
next-generation sequencing (NGS)
p53 protein
TP53 gene
acute myeloid leukemia (AML)
myelodysplastic neoplasias (MDS)
Megjelenés:Cells. - 11 : 21 (2022), p. 1-23. -
További szerzők:Mótyán János András (1981-) (biokémikus, molekuláris biológus) Bedekovics Judit (1986-) (orvos) Miltényi Zsófia (1975-) (belgyógyász, haematológus) Ujfalusi Anikó (1968-) (gyermekorvos, laboratóriumi szakorvos) Méhes Gábor (1966-) (patológus) Mokánszki Attila (1983-) (molekuláris biológus Ph.D hallgató)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1